Pulmonology · Pulmonary EmbolismTrial Updateclinicalmid-term

RAMBO trial evaluates pulmonary rehabilitation's impact post-pulmonary embolism

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/28/2026, 6:02:27 AM

Assessment confidence: 75% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The RAMBO trial's focus on pulmonary rehabilitation for patients with persistent dyspnea post-pulmonary embolism could reshape treatment protocols and enhance patient quality of life. Positive outcomes may lead to increased adoption of rehabilitation strategies, influencing market dynamics for related therapies. Regulatory context from FDA (Cancer Clinical Trial Eligibility Criteria: Laboratory Values) supports the near-term read. Assessment grounded in 4 ranked evidence items (3 high-relevance).

Strategic Assessment

Positive results may lead to increased adoption of pulmonary rehabilitation in clinical practice, impacting market dynamics for related therapies. The strongest clinical anchor is Digital Course and Precision Rehabilitation for Knee Osteoarthritis and Older Adults: Integration of Multisensory Stimulation and Digital Twin Technology (ClinicalTrials.gov), sub-indication match (nmus rehab). In nmus rehab, 0 regulatory and 1 competitive items passed relevance filtering for clinical guidelines for PE management.

Competitive Pressure

The most relevant competitive pressure comes from Ultomiris Phase III trial fails to meet primary endpoint in HSCT-TMA (Humanexa Signals) — sponsor/company relevance (astrazeneca). This trial could influence treatment protocols for pulmonary embolism, particularly in managing long-term symptoms and improving patient quality of life.

Regulatory Outlook

Regulatory risk is concentrated around Positive trial results may prompt updates to clinical guidelines and potential regulatory changes regarding the approval and reimbursement of pulmonary rehabilitation programs..

Key Risks

Elevated medium regulatory exposure for clinical guidelines for PE management could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If pulmonary rehabilitation is validated as an effective treatment, it could lead to a shift in market share towards rehabilitation therapies, impacting revenue for existing pulmonary embolism treatments.
Positive results may lead to increased adoption of pulmonary rehabilitation in clinical practice, impacting market dynamics for related therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent changes in clinical guidelines regarding pulmonary rehabilitation for PE patients.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Cancer Clinical Trial Eligibility Criteria: Laboratory Values
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Expedited IND Pilot Program Educational Webinar for Stakeholders - 08/06/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials - 08/27/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Clinical trials for medicines: collection, verification and reporting of safety events
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Digital Course and Precision Rehabilitation for Knee Osteoarthritis and Older Adults: Integration of Multisensory Stimulation and Digital Twin Technology
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Ultomiris Phase III trial fails to meet primary endpoint in HSCT-TMA
Humanexa Signalsmedium relevance
Sponsor/company relevance (AstraZeneca)

Analgesic effect of premixed nitrous oxide in postoperative rehabilitation for ankle fractures: a randomized controlled trial.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Evaluating AI in postoperative rehabilitation of axillary web syndrome after breast cancer surgery: ChatGPT vs DeepSeek.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

clinical guidelines for PE management

Commercial impact

medium

If pulmonary rehabilitation is validated as an effective treatment, it could lead to a shift in market share towards rehabilitation therapies, impacting revenue for existing pulmonary embolism treatments.

Regulatory impact

medium

Positive trial results may prompt updates to clinical guidelines and potential regulatory changes regarding the approval and reimbursement of pulmonary rehabilitation programs.

What to watch

Monitor trial results and any subsequent changes in clinical guidelines regarding pulmonary rehabilitation for PE patients.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.